Vermillion Scores Patent on Cancer Test (VRML)
Shares of diagnostics company Vermillion Inc. (NASDAQ: VRML) have jumped more than 20% this morning following the company’s announcement of a patent approval for another of its biomarkers used to diagnose ovarian cancer. Today’s approval covers the use of “Protein…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
The company’s CEO said:
The latest patent allowance further strengthens the ovarian cancer franchise behind our lead product, OVA1®, and offers creative new options to detect and manage this silent killer.
Vermillion’s shares are up 22% at $2.08 in a 52-week range of $0.97-$7.60. Volume is very heavy, already at 5x the daily average of about 522,000 shares traded.
Contact [email protected] for any questions or corrections.
Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.
He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.
